Analyst sentiment on ISRG

PARAGRAPH 1 --- What happened: Intuitive Surgical (ISRG) shares plummeted after the company provided muted full-year guidance, despite beating Q2 earnings estimates. This triggered a wave of price target cuts from Wall Street analysts, with Deutsche Bank reducing its target to $366 from $440 and maintaining a 'Sell' rating. ISRG's relative strength index (RSI) fell into the early 30s, indicating the stock is approaching oversold territory. Meanwhile, analysts at Goldman Sachs and Piper Sandler expressed bullish views, highlighting ISRG's long-term growth catalysts and strong market position.

PARAGRAPH 2 --- Market impact: The bearish sentiment drove ISRG's stock price down, affecting investors with exposure to the medical technology sector. The sell-off also raised concerns about the broader robotics and healthcare industries, as ISRG is a prominent player in the robotic surgery market. The differing analyst opinions created market uncertainty, with some investors seeing ISRG as a bargain while others view it as overvalued.

PARAGRAPH 3 --- What to watch next: ISRG's Q3 earnings report, scheduled for October 2022, will provide insight into the company's near-term performance and address any lingering concerns about its guidance. Additionally, investors should monitor regulatory developments surrounding robotic surgery, as these could impact ISRG's competitive landscape. Lastly, ISRG's stock price action around the $360 level, where Deutsche Bank has set its price target, may indicate a potential support or resistance level.